Funding Round attributes
Aignostics, an AI-driven pathology firm based in Berlin, has raised $34 million in a Series B funding round to advance its digital pathology solutions for the pharmaceutical sector. The round was led by ATHOS, with contributions from the Mayo Clinic, High-Tech Gründerfonds (HTGF), and other notable investors, including Wellington Partners and Boehringer Ingelheim Venture Fund.
Founded in 2018 as a spin-off from Charité Berlin, Aignostics leverages artificial intelligence to enhance precision in pathology, aiding in the discovery of diagnostic markers and therapeutic targets. This funding will enable the company to expand its presence in the United States and support its ongoing collaboration with Mayo Clinic to develop foundational models for digital pathology. These models are intended to aid biopharmaceutical companies by accelerating drug research and fostering advancements in precision medicine.
With a focus on digital pathology, Aignostics offers tools for analyzing complex tissue patterns, facilitating new insights in biomarker identification and drug development. The support from Mayo Clinic strengthens Aignostics' approach by bringing in expertise from one of the world’s leading medical centers, underscoring the impact of AI on future pathology practices.
Aignostics' use of AI aims to streamline workflows and increase diagnostic accuracy, enabling pathologists to generate more insightful data to inform medical research. This funding marks a significant step for Aignostics as it expands its impact within digital pathology, catering specifically to the needs of the biopharmaceutical industry in developing new therapeutic approaches.
